Picture EBD Group BioPharm America 2019 Boston September 600x60px
Person › Details

Ken Larkin (London BioScience Innovation Centre (LBIC))

Larkin, Ken (Univ London 201301 CEO of London BioScience Innovation Centre)


Organisation Organisation London BioScience Innovation Centre (LBIC)
  Group University of London
Products Product business park management / science park management
  Product 2 BIOTECH

PolyTherics Ltd.. (1/31/13). "Press Release: PolyTherics Expands London Operations". London.

Expansion driven by growing interest in ThioBridge™ technology for enhancing antibody-drug conjugates technology enables the pharmaceutical industry to develop better treatments for many forms of cancer

PolyTherics Limited ("PolyTherics"), a provider of solutions to enable the development of better biopharmaceuticals, announces that it is expanding its operations at the London Bioscience Innovation Centre in response to rapidly increasing interest in its novel antibody-drug conjugate (ADC) linker technology, ThioBridge™.

Antibody-drug conjugates are becoming established as the next generation of biopharmaceutical products for the treatment of various forms of cancer. ADCs combine the targeting power of antibodies or antibody fragments to deliver cytotoxic agents directly to the tumour, increasing the therapeutic window of the drug and reducing their typical side-effects.

ThioBridge™ is a technology that enables PolyTherics and its partners to develop ADCs with important performance advantages over ADCs developed using other technologies. ThioBridge™ works by linking the drug component of the ADC to the antibody or other targeting molecule at a specific site in its structure (i.e. at a disulfide bridge).

PolyTherics is receiving significant interest in the ThioBridge™ technology from companies ranging from early-stage biotech through to top-ten pharmaceutical companies. In 2012, PolyTherics announced research collaborations with Spirogen (UK) and Biotecnol (US) to develop novel ADCs that leverage its ThioBridge™ technology and is expecting to announce further deals through 2013.

This increasing interest in and focus on its ADC technology and business in the past year has led PolyTherics to expand its research capabilities at the London Bioscience Innovation Centre, nearly doubling its floor space to 7,000 sq ft and recruiting seven additional scientists across a range of disciplines, including an experienced manager for the Company's expanded synthetic chemistry team.

Dr John Burt, PolyTherics' CEO, said: "PolyTherics' expansion reflects our rapid progress in advancing the development of better biopharmaceuticals through the application of our technologies, particularly our ThioBridge™ ADC linker capabilities. While there have been significant improvements in the development of next-generation targeted ADC cancer therapy, creating stable products through the linker technology carrying the toxic payload remains a challenge. We believe our site-specific ThioBridge™ technology has the potential to create better ADCs and look forward to announcing further news over the coming months."

Dr Ken Larkin, CEO of the London BioScience Innovation Centre, said: "We are delighted to support PolyTherics' latest expansion, this is great news for life sciences in London and high-tech companies investing in the Capital."

Record changed: 2015-10-17


Picture [LSUS] – The Business Web Portal 650x112px

More documents for Ken Larkin

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top